GlassScriptPhysician profile
Rajwinder Kaur
NPI 1083265565
$6,344.99
in general payments reported to CMS, 2019-2025
39 companies · $1,150 in 2025
The $1,150 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $986 · 2022: $1,520 · 2023: $1,481 · 2024: $1,208 · 2025: $1,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,839.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,030.10 | 2021-2024 | |
| Glaxosmithkline, LLC. | $696.43 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $628.35 | 2023-2025 | Fasenra, Airsupra, Tezspire |
| Amgen INC. | $513.96 | 2022-2025 | Tezspire, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $464.35 | 2022-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| United Therapeutics Corporation | $218.82 | 2023-2025 | Tyvaso, Tyvaso, Orenitram |
| Scilex Pharmaceuticals INC. | $215.75 | 2021-2022 | |
| Redhill Biopharma INC. | $214.07 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $207.84 | 2021-2022 | |
| Harmony Biosciences LLC | $181.31 | 2023-2024 | Wakix |
| Biohaven Pharmaceutical Holding Company LTD. | $154.18 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $148.49 | 2023-2025 | Opsumit, Uptravi |
| Genzyme Corporation | $143.36 | 2024-2025 | |
| Medtronic, INC. | $140.29 | 2021-2022 | |
| Verona Pharma, INC. | $116.96 | 2025 | Ohtuvayre |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $115.99 | 2021 | |
| Grifols USA, LLC | $104.76 | 2022-2025 | Prolastin-C Liquid |
| Insmed, INC. | $87.54 | 2023-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $86.53 | 2022-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $80.45 | 2023-2024 | |
| Grt US Holding, INC. | $77.21 | 2021 | |
| Forte Bio-Pharma LLC | $75.84 | 2021 | |
| Novartis Pharmaceuticals Corporation | $73.75 | 2023-2024 | |
| Supernus Pharmaceuticals, INC. | $66.35 | 2021 | |
| Pulmonx Corporation | $62.83 | 2023-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Baxter Healthcare | $53.14 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Boston Scientific Corporation | $50.63 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.47 | 2021 | |
| Electromed, INC. | $47.65 | 2025 | Smartvest |
| Pfizer INC. | $39.66 | 2021 | |
| Axsome Therapeutics, INC. | $27.81 | 2024 | Sunosi |
| Pacira Pharmaceuticals Incorporated | $26.05 | 2023 | Zilretta, Iovera |
| La Jolla Pharmaceutical Company | $24.74 | 2023 | Giapreza |
| Regeneron Healthcare Solutions, INC. | $24.72 | 2024 | Dupixent |
| Alk-Abello, INC | $24.38 | 2025 | Grastek, Odactra |
| Takeda Pharmaceuticals U.S.A., INC. | $21.87 | 2023 | Glassia |
| Alexion Pharmaceuticals, INC. | $20.37 | 2022 | |
| Viatris Specialty LLC | $16.39 | 2025 | Yupelri |
| Hikma Pharmaceuticals USA | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajwinder Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.